163 related articles for article (PubMed ID: 37386497)
21. Cytotoxic and radiosensitizing effects of FAK targeting in human glioblastoma cells in vitro.
Storch K; Sagerer A; Cordes N
Oncol Rep; 2015 Apr; 33(4):2009-16. PubMed ID: 25625667
[TBL] [Abstract][Full Text] [Related]
22. Magnetic targeting of paclitaxel-loaded poly(lactic-
Ganipineni LP; Ucakar B; Joudiou N; Bianco J; Danhier P; Zhao M; Bastiancich C; Gallez B; Danhier F; Préat V
Int J Nanomedicine; 2018; 13():4509-4521. PubMed ID: 30127603
[TBL] [Abstract][Full Text] [Related]
23. Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma.
Kesarwani P; Prabhu A; Kant S; Kumar P; Graham SF; Buelow KL; Wilson GD; Miller CR; Chinnaiyan P
Clin Cancer Res; 2018 Aug; 24(15):3632-3643. PubMed ID: 29691296
[No Abstract] [Full Text] [Related]
24. A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
Prabhu S; Goda JS; Mutalik S; Mohanty BS; Chaudhari P; Rai S; Udupa N; Rao BSS
Nanoscale; 2017 Aug; 9(30):10919-10932. PubMed ID: 28731079
[TBL] [Abstract][Full Text] [Related]
25. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Jendrossek V; Belka C; Bamberg M
Expert Opin Investig Drugs; 2003 Dec; 12(12):1899-924. PubMed ID: 14640936
[TBL] [Abstract][Full Text] [Related]
26. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress.
Liu Y; Fang S; Sun Q; Liu B
Biochem Biophys Res Commun; 2016 Nov; 480(3):415-421. PubMed ID: 27771251
[TBL] [Abstract][Full Text] [Related]
27. The making of the glioblastoma classification.
Lasorella A; Iavarone A
Br J Cancer; 2021 Jul; 125(1):4-6. PubMed ID: 33767415
[TBL] [Abstract][Full Text] [Related]
28. LAT1, a novel pharmacological target for the treatment of glioblastoma.
Cappoli N; Jenkinson MD; Dello Russo C; Dickens D
Biochem Pharmacol; 2022 Jul; 201():115103. PubMed ID: 35618000
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological targeting of Tripartite Motif Containing 24 for the treatment of glioblastoma.
Han M; Sun Y
J Transl Med; 2021 Dec; 19(1):505. PubMed ID: 34886858
[TBL] [Abstract][Full Text] [Related]
30. Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.
Schnöller LE; Piehlmaier D; Weber P; Brix N; Fleischmann DF; Nieto AE; Selmansberger M; Heider T; Hess J; Niyazi M; Belka C; Lauber K; Unger K; Orth M
Radiat Oncol; 2023 Mar; 18(1):51. PubMed ID: 36906590
[TBL] [Abstract][Full Text] [Related]
31. Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.
Tan Q; Yan X; Song L; Yi H; Li P; Sun G; Yu D; Li L; Zeng Z; Guo Z
Med Sci Monit; 2017 Aug; 23():4117-4125. PubMed ID: 28842551
[TBL] [Abstract][Full Text] [Related]
32. Tunneling nanotubes: A bridge for heterogeneity in glioblastoma and a new therapeutic target?
Venkatesh VS; Lou E
Cancer Rep (Hoboken); 2019 Dec; 2(6):e1185. PubMed ID: 32729189
[TBL] [Abstract][Full Text] [Related]
33. ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.
Cam M; Charan M; Welker AM; Dravid P; Studebaker AW; Leonard JR; Pierson CR; Nakano I; Beattie CE; Hwang EI; Kambhampati M; Nazarian J; Finlay JL; Cam H
Neuro Oncol; 2020 Mar; 22(3):345-356. PubMed ID: 31763674
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma.
Spencer D; Yu D; Morshed RA; Li G; Pituch KC; Gao DX; Bertolino N; Procissi D; Lesniak MS; Balyasnikova IV
Theranostics; 2019; 9(7):2071-2083. PubMed ID: 31037157
[TBL] [Abstract][Full Text] [Related]
35.
Gallego L; Ceña V
Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
[TBL] [Abstract][Full Text] [Related]
36. Novel Targeting of Transcription and Metabolism in Glioblastoma.
Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
[No Abstract] [Full Text] [Related]
37. Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.
Wallace GC; Dixon-Mah YN; Vandergrift WA; Ray SK; Haar CP; Mittendorf AM; Patel SJ; Banik NL; Giglio P; Das A
Metab Brain Dis; 2013 Sep; 28(3):355-66. PubMed ID: 23543207
[TBL] [Abstract][Full Text] [Related]
38. Current medical treatment of glioblastoma.
Venur VA; Peereboom DM; Ahluwalia MS
Cancer Treat Res; 2015; 163():103-15. PubMed ID: 25468228
[TBL] [Abstract][Full Text] [Related]
39. The NFκB pathway: a therapeutic target in glioblastoma.
Nogueira L; Ruiz-Ontañon P; Vazquez-Barquero A; Moris F; Fernandez-Luna JL
Oncotarget; 2011 Aug; 2(8):646-53. PubMed ID: 21896960
[TBL] [Abstract][Full Text] [Related]
40. Novel Strategies to Discover Effective Drug Targets in Metabolic and Immune Therapy for Glioblastoma.
Wang G; Fu XL; Wang JJ; Guan R; Tang XJ
Curr Cancer Drug Targets; 2017; 17(1):17-39. PubMed ID: 27562399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
